G
Gennao Bio
Gennao Bio is pioneering the development of targeted nucleic acid therapeutics using its unique, non-viral GMAB platform technology
About Gennao Bio
Gennao Bio is a biotech startup that specializes in the development of targeted nucleic acid therapeutics. The company's proprietary technology, GMAB, is a non-viral platform that uses a unique cell-penetrating antibody to deliver nucleic acid payloads to specific cells. This technology is primarily focused on applications in oncology and rare monogenic skeletal muscle diseases.
Read full description
The GMAB technology works by binding to and delivering a wide range of nucleic acid payloads, including various types of RNA and DNA. The GMAB complexes can be delivered into both the cytoplasm and the nucleus of cells, targeting the nucleoside transporter ENT2. This transporter is highly expressed on tumor cells and skeletal muscle, allowing for precise targeting and minimizing off-target effects.
The company's business model revolves around the development and commercialization of this technology. They generate revenue through the licensing of their technology to other companies in the medical field, as well as through the development and sale of their own therapeutic products.
Gennao Bio's technology offers several advantages over traditional genetic medicines. The GMAB complexes avoid the endocytic pathway, the typical internalization mechanism for genetic medicines, which increases the bioavailability of the payload in the cell. The technology also allows for repeat dosing and dose adjustments, and is safe and well-tolerated according to clinical data. Furthermore, the manufacturing process is scalable and reproducible, and the regulatory process is well-defined.
At a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Hopewell Township, United States
- Employees
- 5
- Open positions
- None listed
- Dealroom signal
- 59.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Medical Research, Research and Development, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Dec 2021 | $1M | $200M | Cure Duchenne | ↗ |
| SERIES A✓Equity / VC | May 2021 | $40M | $160M | Citadel · Logos Capital · OrbiMed | ↗ |
Growth signals
Latest recorded traffic for Gennao Bio is 930 monthly website visits, up 220.7% over the last three months. Gennao Bio's team declined 16.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Logos Capital
OrbiMed
Citadel
Cure Duchenne
Other known investors2 additional known investors
Yale University
Yale Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Gennao Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Gennao Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.